BASF Aims for Top Spot in Omega-3 API Market with Pronova BioPharma Acquisition

Heather Cartwright
{"title":"BASF Aims for Top Spot in Omega-3 API Market with Pronova BioPharma Acquisition","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I12.1858","DOIUrl":null,"url":null,"abstract":"In order to attain a leading position in the global omega-3 API market, the German chemical company BASF has made a voluntary offer to acquire Pronova BioPharma, the originator of the blockbuster omega-3 derived drug Lovaza®/Omacor® (omega-3-acid ethyl esters), for a total enterprise value of NOK4845 M (US$844 M). The deal follows BASF’s May 2012 acquisition of Equateq, a UK-based manufacturer of concentrated omega-3 fatty acids.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"62 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I12.1858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In order to attain a leading position in the global omega-3 API market, the German chemical company BASF has made a voluntary offer to acquire Pronova BioPharma, the originator of the blockbuster omega-3 derived drug Lovaza®/Omacor® (omega-3-acid ethyl esters), for a total enterprise value of NOK4845 M (US$844 M). The deal follows BASF’s May 2012 acquisition of Equateq, a UK-based manufacturer of concentrated omega-3 fatty acids.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
巴斯夫收购普罗诺瓦生物制药,力争在欧米伽-3原药市场占据领先地位
为了在全球omega-3原药市场占据领先地位,德国化工公司巴斯夫(BASF)自愿收购proprova BioPharma,该公司是畅销的omega-3衍生药物Lovaza®/Omacor®(omega-3-酸乙酯)的创始人,企业总价值为4845万挪威克朗(8.44亿美元),此前巴斯夫于2012年5月收购了英国浓缩omega-3脂肪酸制造商Equateq。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
IMS PharmaDeals Review of 2014 Juno Therapeutics and Editas Medicine Collaborate to Develop Next-Generation CAR-T Therapeutics Using CRISPR/Cas9 AstraZeneca Bolsters Immuno-Oncology Portfolio via Deals with Celgene and Innate Pharma AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential BMS Bets US$800 M Upfront That Flexus’ Preclinical IDO1 Inhibitor Is Best-in-Class
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1